Kringle Pharma Reports Flat Sales and Continued Losses

Kringle Pharma, Inc. ( (JP:4884) ) just unveiled an update.

Kringle Pharma, Inc. reported its financial results for the quarter ending December 31, 2024, showing net sales of 18 million yen, which remained flat compared to the previous year. However, the company experienced an operating and ordinary profit loss of 212 million yen, indicating ongoing financial challenges. The financial forecast for the fiscal year ending September 30, 2025, suggests expected net sales of 272 million yen with a projected loss continuing, reflecting the company’s ongoing struggle to improve profitability.

More about Kringle Pharma, Inc.

Kringle Pharma, Inc. is a company listed on the Tokyo Stock Exchange, identified by the code number 4884. The company is involved in the pharmaceutical industry and is focusing on developing innovative medical solutions.

YTD Price Performance: -9.74%

Average Trading Volume: 166,577

Technical Sentiment Consensus Rating: Buy

Current Market Cap: Yen5.41B

For detailed information about 4884 stock, go to TipRanks’ Stock Analysis page.